{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:34:39Z","timestamp":1761921279614,"version":"3.37.3"},"reference-count":68,"publisher":"American Society of Hematology","issue":"17","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,10]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Covalent Bruton tyrosine kinase inhibitors (cBTKis), which bind to the BTK C481 residue, are now primary therapeutics for chronic lymphocytic leukemia (CLL). Alterations at C481, primarily C481S, prevent cBTKi binding and lead to the emergence of resistant clones. Pirtobrutinib is a noncovalent BTKi that binds to both wild-type (WT) and C481S-mutated BTK and has shown efficacy in BTK-WT and -mutated CLL patient groups. To compare baseline clinical, transcriptomic, and proteomic characteristics and their changes during treatment in these 2 groups, we used 67 longitudinal peripheral blood samples obtained during the first 3 cycles of treatment with pirtobrutinib from 18 patients with CLL (11 BTK-mutated, 7 BTK-WT) enrolled in the BRUIN (pirtobrutinib in relapsed or refractory B-cell malignancies) trial. Eastern Cooperative Oncology Group performance status, age, and Rai stage were similar in both groups. At baseline, lymph nodes were larger in the BTK-mutated cohort. All patients achieved partial remission within 4 cycles of pirtobrutinib. Lactate dehydrogenase and \u03b22-microglobulin levels decreased in both cohorts after 1 treatment cycle. Expression analysis demonstrated upregulation of 35 genes and downregulation of 6 in the BTK-mutated group. Gene set enrichment analysis revealed that the primary pathways enriched in BTK-mutated cells were involved in cell proliferation, metabolism, and stress response. Pathways associated with metabolism and proliferation were downregulated in both groups during pirtobrutinib treatment. Proteomic data corroborated transcriptomic findings. Our data identified inherent differences between BTK-mutated and -WT CLL and demonstrated molecular normalization of plasma and omics parameters with pirtobrutinib treatment in both groups.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012360","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T17:10:47Z","timestamp":1720199447000},"page":"4487-4501","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib"],"prefix":"10.1182","volume":"8","author":[{"given":"Burcu","family":"Aslan","sequence":"first","affiliation":[{"name":"1Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganiraju","family":"Manyam","sequence":"additional","affiliation":[{"name":"2Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6992-7910","authenticated-orcid":false,"given":"Lakesla R.","family":"Iles","sequence":"additional","affiliation":[{"name":"1Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8732-562X","authenticated-orcid":false,"given":"Shady I.","family":"Tantawy","sequence":"additional","affiliation":[{"name":"1Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1157-6489","authenticated-orcid":false,"given":"Sai Prasad","family":"Desikan","sequence":"additional","affiliation":[{"name":"3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Wierda","sequence":"additional","affiliation":[{"name":"3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3172-9166","authenticated-orcid":false,"given":"Varsha","family":"Gandhi","sequence":"additional","affiliation":[{"name":"1Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"issue":"16","key":"2024091012504249400_bib1","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1182\/blood-2011-06-338855","article-title":"B-cell receptor signaling in chronic lymphocytic leukemia","volume":"118","author":"Stevenson","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2024091012504249400_bib2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2024091012504249400_bib3","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1056\/NEJMra1908213","article-title":"Treatment of chronic lymphocytic leukemia","volume":"383","author":"Burger","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2024091012504249400_bib4","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41375-021-01123-6","article-title":"BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib","volume":"35","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"Leukemia"},{"issue":"20","key":"2024091012504249400_bib5","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1182\/bloodadvances.2022008325","article-title":"Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance","volume":"6","author":"Blombery","year":"2022","journal-title":"Blood Adv"},{"key":"2024091012504249400_bib6","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3389\/fcell.2020.00865","article-title":"Bruton\u2019s tyrosine kinase (BTK) inhibitor RN486 overcomes ABCB1-mediated multidrug resistance in cancer cells","volume":"8","author":"Dong","year":"2020","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"2024091012504249400_bib7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1124\/jpet.111.187740","article-title":"RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents","volume":"341","author":"Xu","year":"2012","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"12","key":"2024091012504249400_bib8","doi-asserted-by":"crossref","first-page":"e127566","DOI":"10.1172\/jci.insight.127566","article-title":"Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity","volume":"4","author":"Wang","year":"2019","journal-title":"JCI Insight"},{"issue":"10","key":"2024091012504249400_bib9","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1158\/2159-8290.CD-17-1409","article-title":"The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and Richter transformation","volume":"8","author":"Reiff","year":"2018","journal-title":"Cancer Discov"},{"issue":"suppl 1","key":"2024091012504249400_bib10","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood-2021-148672","article-title":"Preliminary efficacy and safety of MK-1026, a non-covalent inhibitor of wild-type and C481S mutated Bruton tyrosine kinase, in B-cell malignancies: a phase 2 dose expansion study","volume":"138","author":"Woyach","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2024091012504249400_bib11","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2017-10-809020","article-title":"Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL","volume":"132","author":"Reiff","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2024091012504249400_bib12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3324\/haematol.2021.279158","article-title":"Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase","volume":"107","author":"Aslan","year":"2022","journal-title":"Haematologica"},{"issue":"4","key":"2024091012504249400_bib13","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2021.280061","article-title":"Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton\u2019s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies","volume":"107","author":"Allan","year":"2022","journal-title":"Haematologica"},{"issue":"3","key":"2024091012504249400_bib14","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41419-022-04684-1","article-title":"Dual BTK\/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma","volume":"13","author":"Thieme","year":"2022","journal-title":"Cell Death Dis"},{"issue":"5","key":"2024091012504249400_bib15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-022-00675-9","article-title":"Pirtobrutinib inhibits wild-type and mutant Bruton\u2019s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia","volume":"12","author":"Aslan","year":"2022","journal-title":"Blood Cancer J"},{"issue":"10277","key":"2024091012504249400_bib16","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"2024091012504249400_bib17","first-page":"62","article-title":"Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor","volume":"142","author":"Gomez","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2024091012504249400_bib18","doi-asserted-by":"crossref","first-page":"9368","DOI":"10.1182\/blood-2022-159425","article-title":"Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed\/refractory mantle cell lymphoma: additional patients and extended follow-up from the phase 1\/2 BRUIN study","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024091012504249400_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024091012504249400_bib20","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.clml.2022.02.005","article-title":"SOHO state of the art updates and next questions: targeted therapies and emerging novel treatment approaches for Waldenstr\u00f6m macroglobulinemia","volume":"22","author":"Sermer","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 2","key":"2024091012504249400_bib21","doi-asserted-by":"crossref","first-page":"S394","DOI":"10.1016\/S2152-2650(22)01569-5","article-title":"MCL-133 pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: updated results from the phase 1\/2 BRUIN study","volume":"22","author":"Cohen","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 2","key":"2024091012504249400_bib22","doi-asserted-by":"crossref","first-page":"S395","DOI":"10.1016\/S2152-2650(22)01570-1","article-title":"MCL-135 BRUIN MCL-321, a phase 3 open-label, randomized study of pirtobrutinib versus investigator choice of BTK inhibitor in patients with previously treated, BTK inhibitor na\u00efve mantle cell lymphoma (trial in progress)","volume":"22","author":"Ito","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"S2","key":"2024091012504249400_bib23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/hon.41_2880","article-title":"Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent BTK inhibitor in previously treated Richter transformation: results from the phase 1\/2 BRUIN study","volume":"39","author":"Jurczak","year":"2021","journal-title":"Hematol Oncol"},{"issue":"2","key":"2024091012504249400_bib24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0145-2126(98)00154-4","article-title":"MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation","volume":"23","author":"Stacchini","year":"1999","journal-title":"Leuk Res"},{"issue":"16","key":"2024091012504249400_bib25","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1182\/bloodadvances.2020003821","article-title":"Development and characterization of prototypes for in\u00a0vitro and in\u00a0vivo mouse models of ibrutinib-resistant CLL","volume":"5","author":"Aslan","year":"2021","journal-title":"Blood Adv"},{"issue":"9","key":"2024091012504249400_bib26","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/bloodadvances.2022008447","article-title":"Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance","volume":"7","author":"Naeem","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"2024091012504249400_bib27","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024091012504249400_bib28","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2014-04-565754","article-title":"Blood collection methods affect cellular protein integrity: implications for clinical trial biomarkers and ZAP-70 in CLL","volume":"124","author":"Chen","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2024091012504249400_bib29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"issue":"2","key":"2024091012504249400_bib30","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","article-title":"HTSeq\u2014a Python framework to work with high-throughput sequencing data","volume":"31","author":"Anders","year":"2015","journal-title":"Bioinformatics"},{"issue":"12","key":"2024091012504249400_bib31","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"2024091012504249400_bib32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf"},{"issue":"3","key":"2024091012504249400_bib33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nat Genet"},{"issue":"1","key":"2024091012504249400_bib34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J\u00a0Roy Stat Soc B"},{"issue":"11","key":"2024091012504249400_bib35","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1038\/s41588-022-01140-w","article-title":"Molecular map of chronic lymphocytic leukemia and its impact on outcome","volume":"54","author":"Knisbacher","year":"2022","journal-title":"Nat Genet"},{"issue":"14","key":"2024091012504249400_bib36","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.3390\/ijms20143500","article-title":"Beyond TCR signaling: emerging functions of Lck in cancer and immunotherapy","volume":"20","author":"Bommhardt","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2024091012504249400_bib37","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41467-017-00830-y","article-title":"NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia","volume":"8","author":"M\u00e4rklin","year":"2017","journal-title":"Nat Commun"},{"issue":"5","key":"2024091012504249400_bib38","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1158\/1541-7786.MCR-12-0415-T","article-title":"LCK is an important mediator of B-cell receptor signaling in chronic lymphocytic leukemia cells","volume":"11","author":"Talab","year":"2013","journal-title":"Mol Cancer Res"},{"issue":"1","key":"2024091012504249400_bib39","doi-asserted-by":"crossref","first-page":"16784","DOI":"10.1038\/s41598-017-17021-w","article-title":"Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome","volume":"7","author":"Till","year":"2017","journal-title":"Sci Rep"},{"issue":"6","key":"2024091012504249400_bib40","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.20.00979","article-title":"Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: development and validation of a four-factor prognostic model","volume":"39","author":"Ahn","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"2024091012504249400_bib41","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1182\/blood.2020009741","article-title":"The protein landscape of chronic lymphocytic leukemia","volume":"138","author":"Meier-Abt","year":"2021","journal-title":"Blood"},{"issue":"24","key":"2024091012504249400_bib42","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"2024091012504249400_bib43","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"2024091012504249400_bib44","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024091012504249400_bib45","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"4","key":"2024091012504249400_bib46","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/cncr.31831","article-title":"Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor\u2013resistant chronic lymphocytic leukemia with disease progression and Richter transformation","volume":"125","author":"Kanagal-Shamanna","year":"2019","journal-title":"Cancer"},{"issue":"1","key":"2024091012504249400_bib47","doi-asserted-by":"crossref","first-page":"11589","DOI":"10.1038\/ncomms11589","article-title":"Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition","volume":"7","author":"Burger","year":"2016","journal-title":"Nat Commun"},{"issue":"4","key":"2024091012504249400_bib48","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/leu.2014.263","article-title":"Functional characterization of BTKC481S mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors","volume":"29","author":"Cheng","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"2024091012504249400_bib49","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/s41467-017-02329-y","article-title":"The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy","volume":"8","author":"Landau","year":"2017","journal-title":"Nat Commun"},{"issue":"2","key":"2024091012504249400_bib50","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3390\/cancers13020354","article-title":"Ex vivo mitochondrial respiration parallels biochemical response to ibrutinib in CLL cells","volume":"13","author":"Chowdhury","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"2024091012504249400_bib51","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1182\/blood-2010-09-307249","article-title":"CCL3 (MIP-1\u03b1) plasma levels and the risk for disease progression in chronic lymphocytic leukemia","volume":"117","author":"Sivina","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2024091012504249400_bib52","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"2024091012504249400_bib53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-021-01032-2","article-title":"Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia","volume":"14","author":"Walker","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"key":"2024091012504249400_bib54","doi-asserted-by":"crossref","first-page":"591577","DOI":"10.3389\/fonc.2020.591577","article-title":"Genetic and non-genetic mechanisms of resistance to BCR signaling inhibitors in B cell malignancies","volume":"10","author":"Ondrisova","year":"2020","journal-title":"Front Oncol"},{"issue":"12","key":"2024091012504249400_bib55","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1002\/1878-0261.13386","article-title":"Exportin 1-mediated nuclear\/cytoplasmic trafficking controls drug sensitivity of classical Hodgkin's lymphoma","volume":"17","author":"Caillot","year":"2023","journal-title":"Mol Oncol"},{"issue":"1","key":"2024091012504249400_bib56","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat Commun"},{"issue":"suppl 1","key":"2024091012504249400_bib57","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood-2022-171119","article-title":"Pharmacological profiling of cells from patients with chronic lymphocytic leukemia (CLL) treated with pirtobrutinib","volume":"140","author":"Tantawy","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2024091012504249400_bib58","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood-2022-171203","article-title":"Initial results from a phase 1\/2 dose escalation and expansion study evaluating MS-553, a novel and selective PKC\u03b2 inhibitor, in patients with CLL\/SLL","volume":"140","author":"Blachly","year":"2022","journal-title":"Blood"},{"key":"2024091012504249400_bib59","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/bs.ctdb.2016.09.003","article-title":"ROR-family receptor tyrosine kinases","volume":"123","author":"Stricker","year":"2017","journal-title":"Curr Top Dev Biol"},{"issue":"1","key":"2024091012504249400_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/dvdy.21991","article-title":"Ror-family receptor tyrosine kinases in noncanonical Wnt signaling: their implications in developmental morphogenesis and human diseases","volume":"239","author":"Minami","year":"2010","journal-title":"Dev Dyn"},{"issue":"2","key":"2024091012504249400_bib61","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1172\/JCI83535","article-title":"Wnt5a induces ROR1\/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation","volume":"126","author":"Yu","year":"2016","journal-title":"J\u00a0Clin Invest"},{"issue":"12","key":"2024091012504249400_bib62","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1038\/leu.2017.132","article-title":"Wnt5a induces ROR1 to associate with 14-3-3\u03b6 for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells","volume":"31","author":"Yu","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"2024091012504249400_bib63","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood-2017-12-819383","article-title":"Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1\/2 in chronic lymphocytic leukemia","volume":"132","author":"Hasan","year":"2018","journal-title":"Blood"},{"issue":"25","key":"2024091012504249400_bib64","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood-2016-04-712562","article-title":"High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia","volume":"128","author":"Cui","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2024091012504249400_bib65","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/s41375-022-01543-y","article-title":"High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia","volume":"36","author":"Ghia","year":"2022","journal-title":"Leukemia"},{"issue":"13","key":"2024091012504249400_bib66","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1182\/blood.2019001366","article-title":"Cirmtuzumab blocks Wnt5a\/ROR1 stimulation of NF-\u03baB to repress autocrine STAT3 activation in chronic lymphocytic leukemia","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2024091012504249400_bib67","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/leu.2016.368","article-title":"Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib","volume":"31","author":"Yu","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"2024091012504249400_bib68","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.stem.2018.05.018","article-title":"Phase I trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia","volume":"22","author":"Choi","year":"2018","journal-title":"Cell Stem Cell"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/17\/4487\/2241293\/blooda_adv-2023-012360-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/17\/4487\/2241293\/blooda_adv-2023-012360-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T12:51:49Z","timestamp":1725972709000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/17\/4487\/516845\/Transcriptomic-and-proteomic-differences-in-BTK-WT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":68,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024,9,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012360","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2024,8,28]]}}}